Hypera SA
BOVESPA:HYPE3
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| BR |
|
Hypera SA
BOVESPA:HYPE3
|
16.6B BRL |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
993.5B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
590.8B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
295.5B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
237.8B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
245.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
307.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
153.9B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
123.1B USD |
Loading...
|
Market Distribution
| Min | -6 965.9% |
| 30th Percentile | 2.1% |
| Median | 8.9% |
| 70th Percentile | 15.5% |
| Max | 1 493% |
Other Profitability Ratios
Hypera SA
Glance View
Hypera S.A., a leading force in the Brazilian pharmaceuticals market, has carved a niche by catering to a wide spectrum of health needs through a diverse portfolio. Originally established under the name Hypermarcas, the company took root with the ambition of becoming a pharmaceutical powerhouse in Brazil. This vision was set in motion through strategic organic growth and a series of savvy acquisitions, which helped consolidate its offerings across over-the-counter (OTC) medications, branded prescriptions, dermo-cosmetics, and generics. Each of these segments represents a cog in the machine that drives Hypera’s profitability, with its robust pipeline of drug innovations and strong brand presence ensuring a steady flow of revenue. What truly sets Hypera apart is its ability to harness the synergies between its diverse product lines and an extensive distribution network across Brazil. The company generates revenue not only by selling pharmaceuticals directly to consumers but also through collaborations with healthcare professionals and pharmacies, ensuring its products reach a vast market. Hypera’s commitment to research and development further fuels its growth engine, as it continuously seeks to introduce new drugs and treatments that meet the evolving healthcare demands. The company’s strategic focus on operational efficiency and cost management underpins its financial performance, while its strong brand recognition makes it a preferred choice among consumers and medical professionals alike in Brazil’s dynamic healthcare environment.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Hypera SA is 11.8%, which is below its 3-year median of 18.3%.
Over the last 3 years, Hypera SA’s Net Margin has decreased from 23% to 11.8%. During this period, it reached a low of 11.1% on Jun 30, 2025 and a high of 23% on Sep 30, 2022.